Denali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop and Co-Commercialize DNL593 (PTV:PGRN)

Denali Therapeutics, Inc. announced that its strategic partner Takeda Pharmaceutical Company Limited has exercised an option to co-develop and co-commercialize DNL593, an investigational, brain-penetrant progranulin replacement therapy for the potential treatment of frontotemporal dementia-granulin.